Literature DB >> 22433286

Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study.

Chris J Gardner1, Andrew J Irwin, Christina Daousi, Ian A McFarlane, Franklin Joseph, Jimmy D Bell, E Louise Thomas, Valerie L Adams, Graham J Kemp, Daniel J Cuthbertson.   

Abstract

OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is reported to be more common in patients with GH deficiency (GHD) than in the general population. we aimed to determine: i) liver fat in patients with GHD compared with age and body mass index (BMI)-matched controls; and ii) effect of 6 months of GH replacement (GHR) on liver fat. PARTICIPANTS AND METHODS: The study included 28 GHD patients and 24 controls. 12 patients were studied before and after 6 months of GHR. Anthropometry, liver enzymes and lipid profiles were measured, and body composition and intrahepatocellular lipid (IHCL) were determined by magnetic resonance imaging and spectroscopy.
RESULTS: Age and BMI (median (inter-quartile range)) of patients and controls were 52.6 (14) vs 52.6 (12) years (P=0.9) and 27.8 (24.7, 34.7) vs 27.9 (25.1, 32.1) kg/m(2) (P=0.9). IGF1 was lower in the patients (11.5 vs 16.0 nmol/l, P=0.002). There was no difference in liver transaminases, lipids or IHCL between patients and controls (2.8 (1.3, 8.6) vs 5.0 (1.5, 12.7), P=0.72), despite significantly higher visceral fat in GHD patients. Thirty-two percent of patients and 50% of controls had NAFLD (defined as IHCL >5.6%), and the relationship between IHCL and BMI was the same in each group. GHR significantly reduced abdominal subcutaneous and visceral fat in all patients; however, GHR did not reduce liver fat.
CONCLUSIONS: NAFLD is equally common in patients with GHD and matched controls. GHR is associated with a hierarchical reduction in fat deposition (fat loss: visceral > subcutaneous > liver). Further studies involving GHD patients with NAFLD are required to conclude the role of GHR in treating NAFLD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22433286     DOI: 10.1530/EJE-12-0002

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  18 in total

1.  Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Authors:  Chiara Diazzi; Giulia Brigante; Giulia Ferrannini; Anna Ansaloni; Lucia Zirilli; Maria Cristina De Santis; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Endocrine       Date:  2016-10-11       Impact factor: 3.633

2.  Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice.

Authors:  Rhonda D Kineman; Neena Majumdar; Papasani V Subbaiah; Jose Cordoba-Chacon
Journal:  Endocrinology       Date:  2016-03-07       Impact factor: 4.736

Review 3.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

4.  Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Authors:  Takara L Stanley; Meghan N Feldpausch; Jinhee Oh; Karen L Branch; Hang Lee; Martin Torriani; Steven K Grinspoon
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

5.  Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity.

Authors:  R Dobson; M I Burgess; V S Sprung; A Irwin; M Hamer; J Jones; C Daousi; V Adams; G J Kemp; F Shojaee-Moradie; M Umpleby; D J Cuthbertson
Journal:  Int J Obes (Lond)       Date:  2015-08-14       Impact factor: 5.095

6.  Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice.

Authors:  Jose Cordoba-Chacon; Neena Majumdar; Edward O List; Alberto Diaz-Ruiz; Stuart J Frank; Anna Manzano; Ramon Bartrons; Michelle Puchowicz; John J Kopchick; Rhonda D Kineman
Journal:  Diabetes       Date:  2015-05-26       Impact factor: 9.461

7.  Growth and metabolic outcome in adolescents born preterm (GROWMORE): follow-up protocol for the Newcastle Preterm Birth GRowth study (PTBGS).

Authors:  Claire L Wood; Robert J Tinnion; S Murthy Korada; Timothy D Cheetham; Caroline L Relton; Richard J Cooke; Mark S Pearce; Kieren G Hollingsworth; Michael I Trenell; Nicholas D Embleton
Journal:  BMC Pediatr       Date:  2013-12-20       Impact factor: 2.125

8.  Liver status in congenital, untreated, isolated GH deficiency.

Authors:  Rachel D C A Diniz; Renata M Souza; Roberto Salvatori; Alex Franca; Elenilde Gomes-Santos; Thiago O Ferrão; Carla R P Oliveira; João A M Santana; Francisco A Pereira; Rita A A Barbosa; Anita H O Souza; Rossana M C Pereira; Alécia A Oliveira-Santos; Allysson M P Silva; Francisco J Santana-Júnior; Eugênia H O Valença; Viviane C Campos; Manuel H Aguiar-Oliveira
Journal:  Endocr Connect       Date:  2014-08-12       Impact factor: 3.335

9.  Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study.

Authors:  Lei Xu; Chengfu Xu; Chaohui Yu; Min Miao; Xuequn Zhang; Zhongwei Zhu; Xiaoyun Ding; Youming Li
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

10.  Effects of aerobic exercise on ectopic lipids in patients with growth hormone deficiency before and after growth hormone replacement therapy.

Authors:  Emanuel R Christ; Andrea Egger; Sabin Allemann; Tania Buehler; Roland Kreis; Chris Boesch
Journal:  Sci Rep       Date:  2016-01-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.